With immigration and border security getting attention heading into November’s elections, a large majority of the public reports hearing false claims about immigrants from candidates or elected officials, and many immigrants say the rhetoric is negatively affecting how they are treated, a new KFF Health Misinformation Tracking Poll finds. Fielded before the Sept. 10 debate…More
This brief provides new data from the 2024 KFF Women’s Health Survey on access to fertility care, including women’s opinions about access in their state, cost barriers, and the range of fertility services that women use.
The way we measure ALS progression is failing patients. We are entering a new era of ALS therapeutics but still relying on the same blunt instruments of measurement. The post In the Absence of Objective Measures for ALS, Caregivers are the Only Witnesses. We Shouldn’t Have To Be. appeared first on MedCity News.
The defining capability of modern health plans is intelligent engagement with unified infrastructure. The post Smarter Engagement for Stronger Growth: How Payers Can Successfully Do More with Less appeared first on MedCity News.
Who was Harold Hotelling and what did he contribute to the field of economics? A paper by Gaspard et al. (2024) in the Journal of Economics Literature provides some background on his life, his research and pros and cons of his research contributions. Today I summarize some of his key contributions to the field of…
EMS data is often the earliest signal of a looming public health crisis. By tapping into it in real time, agencies can detect overdose spikes, respiratory surges, or behavioral health trends days before traditional systems catch up. The post The Hidden Frontline of Public Health: How EMS Data Is Powering a New Era of Syndromic…
By STEVEN ZECOLA Recursion Pharmaceuticals announced results today for one its AI-discovered treatments. I was pleased to see the large, sustained reduction in polyps attributable to its treatment for Familial Adenomatous Polyposis. Recursions’ oral medication will be viewed by the traditional scientific and regulatory community as “promising”. On the other hand, I was disappointed not…
AstraZeneca’s Calquence has expanded its FDA approval to include first-line treatment of mantle cell lymphoma. The regulatory decision makes Calquence the first BTK inhibitor approved as an initial treatment for this type of blood cancer. The post FDA Nod Paves Way for AstraZeneca Drug to Become New Standard of Care in Rare Blood Cancer appeared…
Executives say sales have rebounded and are forecasting that the data and technology company’s 2025 top line will be level with last year’s.
Eli Lilly’s new Lilly Employer Connect platform offers employers more flexible access to obesity drugs like Zepbound, but experts say it represents only incremental progress. The post Lilly Employer Connect Adds Flexibility for Employers But Isn’t Revolutionary, Expert Says appeared first on MedCity News.